MAIA Biotechnology, Inc.
MAIA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001878313
In the last 90 days, MAIA Biotechnology, Inc. insiders filed 5 open-market purchases and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $19.4M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding MAIA Biotechnology, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 22 | 20 | −2 |
| Shares | 803.3K | 660.9K | −142.4K (−17.7%) |
| Value | $957.8K | $1.50M | +$545.0K (+56.9%) |
New holders (3)
Institutions that held MAIA Biotechnology, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 32,487 | $71.0K | 0.01% |
| Jane Street Group, LLC | 25,065 | $55.1K | 0.00% |
| Mather Group, LLC. | 24 | $28 | 0.00% |
Sold out (5)
Institutions that held MAIA Biotechnology, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Sabby Management, LLC | 130,510 | $152.7K |
| XTX Topco Ltd | 23,965 | $28.0K |
| Brookstone Capital Management | 12,658 | $14.8K |
| UBS Group AG | 998 | $1.17K |
| Bank of America Corp | 8 | $9 |